An update for urologists and urological teams: Dr Zachary Klaassen's symposium at SESAUA 2025 is now available for viewing on-demand: Cxbladder Triage: Risk Stratification for Patients with Microhematuria. Alongside other key topics, Dr Kaassen discusses the recent inclusion of

News to share! Recognition of Cxbladder’s clinical and economic value in evaluating patients presenting with hematuria is set to gain momentum at the American Urological Association’s (AUA) Annual Meeting, April 26–29 in Las Vegas. Learn more: hubs.ly/Q03jpMWL0

A reminder to all of you who are making the trip to #AUA2025 in Las Vegas this weekend - make sure you come you come visit us at booth #2239. We also invite you to attend one of several sessions focused on Cxbladder's clinical utility and the benefits the suite can bring to your

Great to see so many of you at #AUA2025 today! If you haven't already, make sure you stop by booth #2239. Cxbladder Triage is now included in the AUA Microhematuria Guideline and we'd love to share more detail and explore how this can benefit your clinical practice.

Advancing #microhematuria evaluation: The impact of urinary biomarkers and updated guidelines. Jay Raman Penn State Health & yair lotan UT Southwestern Medical Center sit down with Zach Klaassen Georgia Cancer Center, breaking down the latest in microhematuria evaluation — from 2020–2025 guidelines, to

Advancing Microhematuria Evaluation: The Impact of Urinary Biomarkers and Updated Guidelines. Dr. Jay Raman and Dr. Yair Lotan sit down with Dr. Zachary Klaassen to discuss the latest developments in microhematuria evaluation. Topics include the unmet need in risk stratifying

May is Bladder Cancer Awareness Month, a time for those impacted by #bladdercancer to stand together and raise awareness of the disease while working to enhance its care. Learn more: hubs.ly/Q03l7rhx0 #BCAM25 #BladderCancerMonth25 #BladderCancerAwarenessMonth

Cxbladder Monitor is a genomic urine test that can help ease the burden of invasive testing, reducing the frequency of cystoscopy required in those being monitored for recurrent urothelial non-muscle invasive bladder cancer. Learn more at hubs.ly/Q03lmwS_0 #BCAM25

In December 2023 we surveyed 1,507 US patients being monitored for recurrent non-muscle invasive bladder cancer using BCAN's Patient Survey Network. Those surveyed reported a strong interest in non-invasive test options. Learn more: hubs.ly/Q03m9bMq0 #BCAM25

To increase awareness of our Cxbladder suite of genomic biomarker tests across Asia, the Pacific Edge team, supported by local distributors, schedule regular presentations to urological teams throughout the region. Earlier this month we presented to a team from the Sultan Idris

The Platform Reduces Unnecessary Cystoscopies. Dr. John Sfakianos discusses how Cxbladder is changing the game in microhematuria evaluation and #bladdercancer surveillance. With 99% NPV, Cxbladder Triage and Monitor tests help avoid unnecessary cystoscopies and personalize

Cxbladder Monitor is a genomic urine test that can help ease the burden of invasive testing, reducing the frequency of cystoscopy required in those being monitored for recurrent non-muscle invasive bladder cancer. Learn more at hubs.ly/Q03ngdyt0.

Stay on track. Cxbladder Monitor is a urine-based surveillance alternative that can safely reduce the burden of invasive testing in those being monitored for recurrent non-muscle invasive bladder cancer. In suitable cases, Cxbladdder Monitor can reduce the frequency of cystoscopy

We're proud to co-sponsor this look into the personalized future of pathology with Jay Jhaveri from Pacific Edge Ltd. Discover how genomic testing is enhancing diagnostic accuracy and tailoring treatments. Listen now: lumeadigital.com/genomic-test-r… #PathPulse #Genomics #MedicalTech

Improving Diagnosis and Treatment of Microhematuria: Kaiser Permanente's Dr. Ronald Loo and Dr. Christopher Filson join @ZKlaassen_MD to discuss the real-world implementation of Cxbladder Triage within the Kaiser Health System for risk stratification, including the results of a

AUA Guideline Amendment Chair Dr. Daniel Barocas and Dr. Zachary Klaassen break down the latest AUA Microhematuria Guideline recommendations and how they can enhance clinical practice, sparing patients low-yield, costly or invasive investigations to improve value across the

Advancing Microhematuria Evaluation: The Impact of Urinary Biomarkers and Updated Guidelines. Dr. Jay Raman and Dr. Yair Lotan sit down with Dr. Zachary Klaassen to discuss the latest developments in microhematuria evaluation. Topics include the unmet need in risk stratifying

Host Diane Newman and Pacific Edge Senior Medical Director Dr. Jay Jhaveri discuss key changes incorporated into the 2025 AUA/SUFU Microhematuria Guideline and the implications for clinical practice. The updated Guideline emphasizes refined risk stratification and suggests a more

The Pacific Edge Team invite you to review the July 2025 edition of the Cxbladder Bulletin newsletter: hubs.ly/Q03y7YZ50. Features in this update include: UroToday's recent AUA webinar series, for US clinicians: a Medicare coverage update and information on our customer

The Platform Reduces Unnecessary Cystoscopies. Dr. John Sfakianos discusses how Cxbladder is changing the game in microhematuria evaluation and bladder cancer surveillance. With 99% NPV, Cxbladder Triage and Monitor tests help avoid unnecessary cystoscopies and personalize